Table 1

Baseline characteristics for patients with a DAS>2.2

Total population
(n=120)
Age (years), median (IQR)54 (44–63)
Symptom duration (days), median (IQR)161 (97–210)
Sex, female, no (%)78 (65)
RF positive, no (%)78 (65)
ACPA positive, no (%)84 (70)
Morning stiffness >1 h, no (%)93 (78)
Erosion, no (%)20 (17)
Fulfilment of RA criteria, no (%)
 198782 (68)
 2010114 (95)
DAS, mean (95% CI)3.43 (3.28–3.57)
TJC44, median (IQR)10 (5–15)
SJC44, median (IQR)8 (4–12)
ESR (mm/h), median (IQR)22 (13–39)
General health (0–100 mm), median (IQR)53 (37–66)
Treatment, no (%)
 A. MTX+SSZ+HCQ+GCs IM43 (36)
 B. MTX+SSZ+HCQ+GCs oral39 (33)
 C. MTX+GCs oral38 (32)
  • ACPA, anti-citrullinated peptide antibodies; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; GCs, glucocorticoids; HCQ, hydroxychloroquine; IM, intramuscular; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC44, swollen joint count (44 joints); SSZ, sulfasalazine; TJC44, tender joint count (44 joints).